Hikal develops Favipiravir Active Pharmaceutical ingredient

15 May 2020 Evaluate
Hikal has successfully developed Favipiravir Active Pharmaceutical ingredient (API) and its intermediates. Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co., Japan, a subsidiary of Fujifilm Corporation. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. It is in various stages of clinical trials in many countries as an experimental treatment of COVID-19.

The company is in discussion with potential partners to supply the API and its intermediates.

Hikal has developed this API in a record amount of time to make the product available for treatment of COVID-19. This demonstrates Hikal's commitment to support in the fight against COVID-19 virus and to provide high quality medicines to its customers globally.

Hikal is a leading manufacturer and supplier of API's and intermediates globally.

Hikal Share Price

225.70 -1.95 (-0.86%)
31-Dec-2025 09:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1721.20
Dr. Reddys Lab 1262.00
Cipla 1491.25
Zydus Lifesciences 908.20
Lupin 2087.30
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×